TrialsgrambetaRCTs are beautiful

EMPA-KIDNEY

2023

Study of Heart and Kidney Protection with Empagliflozin

In 6,609 patients across a broad spectrum of CKD, empagliflozin reduced kidney-disease progression or cardiovascular death compared with placebo.

Result

Efficacy: CKD progression or cardiovascular deathHR 0.72 (95% CI 0.64-0.82) · P < 0.001

Below 1 favours empagliflozin, above 1 favours placebo.

Event rates
Absolute difference
3.8 points
NNT
27

Absolute difference and NNT are derived from the event rates.

Original publication
Subtopic
SGLT2 inhibitors
Design
Double-blind RCT, stopped early
Relevance
Important: one of several pillars.
Source
The EMPA-KIDNEY Collaborative Group. N Engl J Med. 2023;388(2):117-127.doi 10.1056/NEJMoa2204233

Discussion & critique

Widest CKD eligibility yet (eGFR down to 20); no significant benefit in the UACR <30 mg/g subgroup.

Discussed in podcasts